122 related articles for article (PubMed ID: 15810085)
1. Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer.
Dong M; Ma G; Tu W; Guo KJ; Tian YL; Dong YT
World J Gastroenterol; 2005 Apr; 11(14):2162-5. PubMed ID: 15810085
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer.
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Histopathology; 2014 Mar; 64(4):523-35. PubMed ID: 24289472
[TBL] [Abstract][Full Text] [Related]
3. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
Yu GZ; Zhu MH; Ni CR; Li FM; Zheng JM; Gong ZJ
Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):130-4. PubMed ID: 15132849
[TBL] [Abstract][Full Text] [Related]
4. [Correlation between Gli1 expression and clinicopathological significance in human pancreatic cancer].
Sheng WW; Dong M; Zhou JP; Liu QF; Li X; Dong Q
Zhonghua Wai Ke Za Zhi; 2013 Oct; 51(10):916-21. PubMed ID: 24433772
[TBL] [Abstract][Full Text] [Related]
5. [The relationship and clinicopathological significance of Numb,MDM2 and p53 expression in human pancreatic cancer].
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Zhonghua Wai Ke Za Zhi; 2014 Sep; 52(9):675-81. PubMed ID: 25410780
[TBL] [Abstract][Full Text] [Related]
6. [Expression and clinical significance of P53 pathway-associated proteins in pancreatic carcinoma].
Yu GZ; Zhu MH; Chen Y; Ni CR; Li FM
Ai Zheng; 2005 Nov; 24(11):1398-403. PubMed ID: 16552971
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.
Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R
J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259
[TBL] [Abstract][Full Text] [Related]
8. [Expressions of p53 and Gadd45a proteins in human pancreatic cancer and their clinicopathological significance].
Dong M; Zhou JP; Kong FM; Guo KJ; Tian YL; Dong YT
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Oct; 27(5):628-32. PubMed ID: 16274047
[TBL] [Abstract][Full Text] [Related]
9. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
10. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.
Dogan E; Saygili U; Tuna B; Gol M; Gürel D; Acar B; Koyuncuoğlu M
Gynecol Oncol; 2005 Apr; 97(1):46-52. PubMed ID: 15790436
[TBL] [Abstract][Full Text] [Related]
11. The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas.
Lam KY; Lo CY; Wat NM; Luk JM; Lam KS
J Clin Pathol; 2001 Jun; 54(6):443-8. PubMed ID: 11376017
[TBL] [Abstract][Full Text] [Related]
12. Cooperation among Numb, MDM2 and p53 in the development and progression of pancreatic cancer.
Sheng W; Dong M; Zhou J; Li X; Liu Q; Dong Q; Li F
Cell Tissue Res; 2013 Nov; 354(2):521-32. PubMed ID: 23881403
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological correlations of cyclooxygenase-2, MDM2, and p53 expressions in surgically resectable pancreatic invasive ductal adenocarcinoma.
Hermanova M; Karasek P; Nenutil R; Kyr M; Tomasek J; Baltasova I; Dite P
Pancreas; 2009 Jul; 38(5):565-71. PubMed ID: 19346994
[TBL] [Abstract][Full Text] [Related]
14. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
[TBL] [Abstract][Full Text] [Related]
15. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
Jahnson S; Karlsson MG
Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
[TBL] [Abstract][Full Text] [Related]
16. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
[TBL] [Abstract][Full Text] [Related]
17. p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder.
Røtterud R; Berner A; Holm R; Skovlund E; Fosså SD
BJU Int; 2001 Aug; 88(3):202-8. PubMed ID: 11488730
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder.
El-Kenawy Ael-M; El-Kott AF; Khalil AM
Int J Biol Markers; 2003; 18(4):284-9. PubMed ID: 14756544
[TBL] [Abstract][Full Text] [Related]
19. Expression of Gadd45a and p53 proteins in human pancreatic cancer: potential effects on clinical outcomes.
Dong M; Dong Q; Zhang H; Zhou J; Tian Y; Dong Y
J Surg Oncol; 2007 Mar; 95(4):332-6. PubMed ID: 17230496
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma--survival and clinical characteristics in relation to various histologic molecular markers in Western patients.
Schöniger-Hekele M; Hänel S; Wrba F; Müller C
Liver Int; 2005 Feb; 25(1):62-9. PubMed ID: 15698400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
